右丙亚胺对蒽环类抗肿瘤药心脏毒性防护研究

Advances in use of cardioxane for prevention of anthracycline- induced cardiac injury

右丙亚胺是作用位点专一的心脏防护药物，能够有效预防蒽环类抗肿瘤药引起的心脏毒性。右丙亚胺已被广泛应用于接受蒽环类抗肿瘤药化疗的患者。临床研究表明，静脉应用右丙亚胺能够显著降低蒽环类抗肿瘤药引起的充血性心力衰竭和严重心脏意外。其不良反应非常小，患者易于耐受。到目前为止，是唯一有效地能够预防蒽环类抗肿瘤药引起的心脏毒性的药物，推荐临床使用。

Cardioxane is a site-specific cardioprotective agent that effectively prevents anthracyclineinduced cardiac toxicity. Cardioxane is approved for use in a wider range of patients with advanced cancer receiving anthracyclines. As shown in clinical trials, intravenous eardioxane significantly reduces the incidence of anthracyeline-induced congestive heart failure （CHF） and severe cardiac events. The drug is generally well tolcrated and has a tolerability profile similar to that of placebo in cancer patients undergoing anthracycline-based chemotherapy. Cardioxane is the only cardioprotective agent with proven efficacy in cancer patients receiving anthracycline chemotherapy and is a valuable option for the prevention of cardiotoxicity in this patients population.